HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1)

Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: 11fd07088538e763e454e45c4c17d93f703c492a
First added on: Feb 07, 2025